<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962867</url>
  </required_header>
  <id_info>
    <org_study_id>NCCH2006/MK010</org_study_id>
    <nct_id>NCT04962867</nct_id>
  </id_info>
  <brief_title>NCCH2006/MK010 Trial (FORTUNE Trial)</brief_title>
  <official_title>Multicenter Investigator-initiated Phase II Trial of E7090 in Patients With Advanced or Recurrent Solid Tumor With Fibroblast Growth Factor Receptor (FGFR) Gene Alteration (FORTUNE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Center, Japan</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, multicenter, investigator-initiated Phase 2 trial to&#xD;
      evaluate the efficacy and safety of E7090 in patients with advanced or recurrent solid tumors&#xD;
      harboring FGFR genetic alterations (including fusion, mutation, amplification).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Overall response rate (ORR) defined as the combined incidence of complete response (CR) and PR, confirmed no less than 4 weeks after the criteria for response are first met, based on RECIST v1.1. ORR will be confirmed by independent blinded central review assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Overall response rate (ORR) defined as the combined incidence of complete response (CR) and PR, confirmed no less than 4 weeks after the criteria for response are first met, based on Response Assessment in Neuro-Oncology (RANO) criteria for primary Central Nervous System (CNS) tumor or RECIST v1.1 for other tumor type. ORR will be confirmed by local site investigator and/or independent blinded central review assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Progression-free survival (PFS) defined as the time from the date of enrollment to the date of the first documentation of objective progression of disease (PD), clinically diagnosed symptomatic deterioration, or death due to any cause in the absence of documented PD, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Overall survival (OS) defined as the time from date of enrollment to date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Disease control rate (DCR) defined as the percentage of patients with a confirmed complete response (CR), partial response (PR) or stable disease (SD) as the best overall according to RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event (AE) rate</measure>
    <time_frame>From the first dose of the investigational product until 30 days after the last dose of study drugs</time_frame>
    <description>Defined as the percentage of patients who experienced each adverse event. The severity of AEs were evaluated by the investigator according to Japan Clinical Oncology Group (JCOG) Japanese translation of the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0-JCOG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reaction (adverse drug reaction) rate</measure>
    <time_frame>From the first dose of the investigational product until 30 days after the last dose of study drugs</time_frame>
    <description>Defined as the percentage of patients who experienced each adverse reaction (causally related to the protocol treatment). The severity of AEs were evaluated by the investigator according to Japan Clinical Oncology Group (JCOG) Japanese translation of the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0-JCOG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Duration of Response (DOR) defined as the time from the date of first documentation of CR or PR to the date of first documentation of disease progression or date of death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>Baseline up to 3.5 years</time_frame>
    <description>Time to response (TTR) defined as the time from the date of first study dose to the date of first documentation of CR or PR according to RECIST version 1.1.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Advanced or Recurrent Solid Tumors</condition>
  <condition>FGFR Gene Alterations</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E7090</intervention_name>
    <description>140 mg of E7090 is orally administered once daily.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants with histologically or cytologically confirmed metastatic, unresectable,&#xD;
             or recurrent solid tumor who agree to provide an archival tumor sample, a residual&#xD;
             biopsy sample, or a fresh tumor biopsy sample&#xD;
&#xD;
          2. Ineffective to or intolerant to initial treatment, or for which standard treatment is&#xD;
             no longer available&#xD;
&#xD;
          3. Participants with an FGFR gene alteration detected by NGS panel, who fall under one of&#xD;
             the categories of groups A to C defined as below&#xD;
&#xD;
             Group A: FGFR1-3 fusion&#xD;
&#xD;
             Group B: FGFR1-3 specific activating mutations as below;&#xD;
&#xD;
             FGFR1: P150S, T340M, R445W, N546K, K656E&#xD;
&#xD;
             FGFR2: C62Y, A67V, N82K, D101Y, E160K, E163K, M186T, R203H, R210Q, Q212K, R251Q,&#xD;
             S252W, P253R, P253L, A264T, W290C, K310R, Y328N, G364E, Y375C, C382R, A389T, V392A,&#xD;
             R399Q, H416R, I422V, H544Q, N549H, N549K, N549D, N549S, L560F, K659E, K659N, R664W,&#xD;
             E718K, S791T&#xD;
&#xD;
             FGFR3: G380E, G380R, A391E, K650T, K650E, K650Q, K650N&#xD;
&#xD;
             Group C: FGFR1-3 activating mutation not applicable to group B, or FGFR1, 2 gene&#xD;
             amplification&#xD;
&#xD;
          4. For Group D, participants with cholangiocarcinoma who have previously received a&#xD;
             selective FGFR inhibitor other than E7090 and have demonstrated progressive disease or&#xD;
             resistance&#xD;
&#xD;
          5. Karnofsky Performance Status (KPS) &gt;= 70 for patients with primary CNS tumors.&#xD;
             Performance Status (ECOG) 0-1 for patients with non-primary CNS tumors&#xD;
&#xD;
          6. For patients with non-primary CNS tumors, they have at least 1 lesion of &gt;= 10&#xD;
             millimeter (mm) in the longest diameter for a non-lymph node or &gt;= 15 mm in the&#xD;
             short-axis diameter for a lymph node that is considered as serially measurable&#xD;
             according to RECIST v1.1 using computerized tomography or magnetic resonance imaging&#xD;
             (CT or MRI) within 28 days of enrollment. However, lesions that have received local&#xD;
             treatment such as external-beam radiation therapy (EBRT) or radiofrequency ablation&#xD;
             (RFA) must have progressed after these local treatment to count as measurable lesion&#xD;
&#xD;
          7. Participants with primary CNS tumors must meet all of the following criteria:&#xD;
&#xD;
               1. Have received prior treatment including radiation and/or chemotherapy, as&#xD;
                  recommended or appropriate for the CNS tumor type&#xD;
&#xD;
               2. Have &gt;= 1 site of bi-dimensionally measurable disease (confirmed by magnetic&#xD;
                  resonance imaging (MRI) and evaluable by RANO criteria), with the size of at&#xD;
                  least one of the measurable lesions &gt;= 1 cm in each dimension and noted on more&#xD;
                  than one imaging slice. Imaging study performed within 28 days before enrollment&#xD;
&#xD;
               3. Must be neurologically stable based on neurologic exam at least for the last 7&#xD;
                  days prior to enrollment. (based on medical examination/interview)&#xD;
&#xD;
          8. Corrected calcium &lt;= 10.1 mg/dL&#xD;
&#xD;
          9. Phosphate &lt;= 4.6 mg/dL&#xD;
&#xD;
         10. Required treatment washout period, from the last day of prior treatment until&#xD;
             enrollment of this trial, is as follows:&#xD;
&#xD;
               1. Antibody and other investigational drugs: &gt;= 28 days&#xD;
&#xD;
               2. Prior chemotherapy (excluding small-molecule targeted therapy), surgical therapy,&#xD;
                  radiation therapy: &gt;= 21 days (&gt;= 90 days from the date of the last radiation&#xD;
                  therapy for primary CNS tumors)&#xD;
&#xD;
               3. Endocrine therapy, immunotherapy, small-molecule targeted therapy: &gt;=14 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with brain, subdural or leptomeningeal metastases&#xD;
&#xD;
          2. Participants with primary CNS tumor located in either cerebellum, brainstem, spinal&#xD;
             cord, pituitary gland, optic nerve or olfactory nerve&#xD;
&#xD;
          3. Positive for either human immunodeficiency virus (HIV) antibody, HBs antigen, or HCV&#xD;
             antibody (patients with positive HCV antibody but no detectable HCV-RNA are not&#xD;
             excluded)&#xD;
&#xD;
          4. Negative for HBs antigen, but positive for HBs antibody or HBc antibody, and also&#xD;
             positive for HBV-DNA quantification (not excluded if HBV-DNA is below detection&#xD;
             sensitivity)&#xD;
&#xD;
          5. Child-Pugh score B or C&#xD;
&#xD;
          6. Participants with pericardial effusion, pleural effusion, or ascites requiring&#xD;
             treatment&#xD;
&#xD;
          7. Have any of the following ocular diseases&#xD;
&#xD;
               1. Grade 2 or higher corneal disorders&#xD;
&#xD;
               2. Active retinopathy (e.g., age-related macular degeneration, central serous&#xD;
                  chorioretinal disease, retinal tear)&#xD;
&#xD;
          8. Participants whose toxicity of previous treatment has not recovered to Grade 1 or&#xD;
             lower per Common Terminology Criteria for Adverse Events (CTCAE v5.0), except for&#xD;
             alopecia, infertility, and the laboratory test results listed in the inclusion&#xD;
             criteria&#xD;
&#xD;
          9. Participants who received a prior selective FGFR inhibitor in the recurrent/metastatic&#xD;
             disease setting; except for patients with cholangiocarcinoma harboring FGFR2 fusion&#xD;
             (Group D). Note that prior use of a multi-kinase inhibitor which includes anti-FGFR&#xD;
             activity is acceptable after review by the lead investigator&#xD;
&#xD;
         10. Participants who need the use of drugs that strongly inhibits or induces the&#xD;
             metabolizing enzyme cytochrome P450 (CYP) 3A&#xD;
&#xD;
         11. The presence of FGFR gatekeeper mutations as follows: FGFR1 V561, FGFR2 V564/565,&#xD;
             FGFR3 V555/557, FGFR4 V550&#xD;
&#xD;
         12. The presence of any of the following coexisting driver gene abnormalities:&#xD;
&#xD;
               1. Genetic mutations (excluding VUS): KRAS, NRAS, EGFR, or BRAF V600&#xD;
&#xD;
               2. Gene translocations: ALK, ROS1, or NTRK&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masamichi Takahashi, M.D., Ph.D.</last_name>
    <phone>+81-3-3542-2511</phone>
    <email>NCCH2006_office@ml.res.ncc.go.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Aoba-ku, Sendai, Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masanobu Takahashi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku, Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masamichi Takahashi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Higashi-Ku, Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Kusaba, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Kita-Ku, Sapporo, Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ichiro Kinoshita, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Sakyo-ku, Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junichi Matsubara, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E7090</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Fibroblast Growth Factor Receptor (FGFR)</keyword>
  <keyword>FGFR inhibitor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

